IGC Pharma (NYSEMKT:IGC – Free Report) had its price target lifted by Ascendiant Capital Markets from $3.50 to $3.75 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.
IGC Pharma Stock Performance
IGC Pharma stock opened at $0.35 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.16 and a current ratio of 1.77. The stock has a market cap of $26.70 million, a price-to-earnings ratio of -1.60 and a beta of 1.27.
About IGC Pharma
Further Reading
- Five stocks we like better than IGC Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- Compound Interest and Why It Matters When Investing
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Where Do I Find 52-Week Highs and Lows?
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.